AustriaAustria

Austria

09.04.2004

Vienna - Igeneon AG has raised a total of Euro26.7 million in venture capital in a financing round. Proceeds will be used to further advance the development of three clinical lead products, two cancer vaccines and a humanized monoclonal antibody.

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-austria/article/austria-12.html

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)2.30 EUR27.78%
  • SAREUM HOLDINGS (UK)0.76 GBP26.67%
  • PROTHENA PLC (IE)55.46 USD7.46%

FLOP

  • RENEURON (UK)3.00 GBP-4.46%
  • PHARMING (NL)0.24 EUR-4.00%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%

TOP

  • PROTHENA PLC (IE)55.46 USD53.2%
  • ACTIVE BIOTECH (S)12.40 SEK34.1%
  • NEWRON (CH)18.75 CHF29.3%

FLOP

  • SANTHERA (CH)55.30 CHF-22.1%
  • MOLOGEN (D)2.30 EUR-20.7%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)30.80 SEK1887.1%
  • NICOX (F)10.85 EUR465.1%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%

FLOP

  • BB BIOTECH (D)45.30 EUR-84.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016

Events

All Events

Partner-Events